Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Avid Bioservices Gained as Much as 17.7% Today, Then Dropped

By Maxx Chatsko - Sep 11, 2018 at 10:58AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The contract biologics manufacturer reported fiscal first-quarter 2019 earnings results.

What happened

Shares of Avid Bioservices ( CDMO 0.82% ) rose nearly 18% today after the company reported fiscal first-quarter 2019 operating results. The business, which provides contract process development and manufacturing services for biopharma customers, reported quarterly revenue of $12.6 million and a net loss of $0.06 per share.  

Both of those totals easily beat Wall Street expectations, which called for just $9 million in revenue and a net loss of $0.13 per share, according to numbers compiled by Yahoo! Finance. That was based on averaging just two estimates, however, which is likely why, as of 10:31 a.m. EDT on Tuesday, the stock had settled to a 1.4% loss.

A chalkboard drawing of a graph showing growth followed by a sudden and sharp decline.

Image source: Getty Images.

So what

On the Q1 2019 earnings conference call, management reaffirmed fiscal full-year 2019 revenue guidance of $51 million to $55 million. That would put Avid Bioservices on pace to roughly match revenue totals from each of the last two fiscal years, but the numbers fail to demonstrate behind-the-scenes progress.

Avid is working on a more diverse customer portfolio, to replace revenue lost from lower demand by its top two customers. While the plan is working, it makes the company appear to be running in place. But with a new process development lab started up in the most recent quarter and a more solid foundation from which to build upon, Avid could be better positioned to more fully capitalize on its niche opportunity in biopharma services in the next few years.

Now what

Avid Bioservices presents an intriguing long-term opportunity for investors interested in owning a piece of the fast-growing biopharma space, while avoiding the risks presented by clinical trials. However, the business' new focus on process development and manufacturing services -- which it only fully pivoted to in fiscal 2018 -- still has a little way to go before ironing out the kinks.

For instance, lower demand from the top two customers resulted in more idle time in the most recent quarter, which sapped gross margin. As the customer base grows and the business expands, underutilization should become a less-pressing concern in the future. But investors should know that the company's business model will take time, perhaps years, to deliver consistent and profitable growth.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Avid Bioservices, Inc. Stock Quote
Avid Bioservices, Inc.
CDMO
$30.80 (0.82%) $0.25

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
635%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.